Life Sciences
Digital | In Person
English
Livestream
Falling Walls Science Breakthroughs
Matthias Tschöp: Breaking the Wall of Obesity
Falling Walls Foundation | Matthias Tschöp
How Novel Drugs Enable Body Weight Control
Overweight individuals face an increased risk of developing various diseases, with diabetes being a prominent concern. Diabetes, both Type 1 and Type 2, can lead to serious complications such as heart disease, kidney failure, blindness, and nerve damage. Obesity exacerbates the body’s insulin resistance, making it challenging for cells to properly regulate blood sugar levels, leading to diabetes.
Matthias Tschöp, CEO of Helmholtz Munich and VP of the Helmholtz Association, is renowned for unraveling fundamental gut-brain signals, leading to the development of highly effective drugs for human obesity.
At Falling Walls, Tschöp will share his significant strides in diabetes research, notably discovering the hunger hormone ghrelin in 2000 and, in collaboration with chemist Richard DiMarchi, pioneering a new class of intestinal hormone drugs called polyagonists.
LIVE EVENT; AVAILABLE VIA LIVESTREAM FREE OF CHARGE FOR LOGGED IN USERS AND ATTENDANCE IN LECTURE HALL. RADIAL, GROUND FL. FOR SUMMIT PARTICIPANTS
Matthias Tschöp is the CEO of Helmholtz Munich, VP of the Helmholtz Association and AvH Professor at the TU of Munich. He unraveled fundamental gut-brain signals to discover the first highly effective drugs for human obesity in collaboration with the chemist Richard DiMarchi – the dual and triple gut hormone multi-agonists. A first representative is FDA-approved. Tschöp has received numerous awards, including the Banting Medal, the Heinrich Wieland Prize and the Ernst Schering Prize. He holds an adjunct professorship at Yale University and an honorary doctorate at Leipzig University. He was elected a member of the German, Bavarian, and European Academies of Sciences, the ASCI and the AAP.
